Results 61 to 70 of about 38,942 (318)

Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial

JAMA ophthalmology, 2018
Importance Ranibizumab is a viable treatment option for eyes with proliferative diabetic retinopathy (PDR) through 2 years. However, longer-term results are needed.
J. Gross, A. Glassman, Danni Liu, Jennifer K. Sun, A. Antoszyk, C. Baker, N. Bressler, M. Elman, F. Ferris, T. Gardner, L. Jampol, Daniel F. Martin, M. Melia, Cynthia R. Stockdale, R. Beck   +14 more
semanticscholar   +1 more source

The results of comparative analysis of angiogenic and laser therapy for diabetic macular edema in diabetes type 2

Oftalʹmologiâ, 2014
Purpose: To compare the results of laser treatment and intravitreal ranibizumab injections in patients with DME consistent with the level of VEGF A in tear fluid.Methods: The progress of visual acuity, retinal thickness and light sensivity after laser ...
I. V. Vorobieva, E. V. Parfenova, D. A. Merkushenkova, P. I. Makarevich, V. I. Alekhnovich   +4 more
doaj   +3 more sources

Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. [PDF]

PLoS ONE, 2014
OBJECTIVE: To evaluate if a standardized combination therapy regimen, utilizing 3 monthly ranibizumab injections followed by navigated laser photocoagulation, reduces the number of total ranibizumab injections required for treatment of diabetic macular ...
Raffael Liegl, Julian Langer, Florian Seidensticker, Lukas Reznicek, Christos Haritoglou, Michael W Ulbig, Aljoscha S Neubauer, Anselm Kampik, Marcus Kernt   +8 more
doaj   +1 more source

Plasma lipoprotein subfraction concentrations are associated with lipid metabolism and age-related macular degeneration [PDF]

, 2017
10.1194/jlr.M073684Journal of Lipid Research5891785 ...
Apte, Rajendra S., Chee, Miao Ling, Cheng, Ching-Yu, Fan, Qiao, Gan, Alfred, Gemmy Cheung, Chui Ming, Khor, Chiea Chuen, Mathur, Ranjana, Tai, E. Shyong, Wong, Tien Yin, Yeo, Ian   +10 more
core   +2 more sources

Intravitreal ranibizumab, with or without filter? [PDF]

Acta Ophthalmologica, 2011
of 30 and 50 years (Yannuzzi 1986; Wang et al. 2008). Rarely, the presentation of exudative retinal detachments has been reported in younger patients in association with leukaemia (Stewart et al. 1989). These three young patients had all of the typical clinical characteristics of CSC, and to our knowledge, there is no previous report of CSC in patients
Eugenia Sanchis-Merino, José M. Ruiz-Moreno, Javier A. Montero   +2 more
openaire   +3 more sources

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto, Greco A., La Cava M, Lambiase A, Limoli PG, Nebbioso M   +5 more
core   +1 more source

Treatment Strategies for Refractory Diabetic Macular Edema: Switching Anti-VEGF Treatments, adopting corticosteroid-based treatments, and combination therapy [PDF]

, 2016
Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators.
Ciulla, Thomas A., Hussain, Rehan M.
core   +1 more source

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

International Journal of Retina and Vitreous, 2021
Background Razumab™ (world’s first biosimilar ranibizumab) is approved for several macular disorders including wet age-related macular degeneration (AMD). We evaluated the safety and efficacy of biosimilar ranibizumab in wet AMD. Methods This prospective,
Shashikant Sharma, Vishali Gupta, A. Maiti, S. Natesh, S. Saxena, V. Dave, Vimal P. Parmar, Raju Sampangi, H. Murthy, Sandhya Dharwadkar, N. Yadav, S. Joshi, Rahul Mayor, D. Ratra, S. Basu, N. Goel, A. Chaturvedi, Ronak Patel, V. Jose   +18 more
semanticscholar   +1 more source

Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study

Ophthalmology and Therapy
Introduction The study aimed to evaluate comparability in terms of efficacy, safety and immunogenicity of Sun’s ranibizumab biosimilar with reference ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
Asim K. Ghosh, Usha S. Nikumbh, Chaitanya K. Shukla, Rohit S. Laul, Abhishek Dixit, Santosh K. Mahapatra, Sameera Nayak, Urmil M. Shah, Sandeep Parwal, Narendran Venkatapathy, Natasha Radhakrishnan, Anup Kelgaonkar, Sandeep Saxena, Divyansh Mishra, Vivek Pravin Dave, Perwez Khan, Manojkumar R. Saswade, Malli S. Shantilal, Kim Ramasamy, Smitha Sreekanta, Mandodari Rajurkar, Maulik Doshi, Sapan Behera, Piyush Patel, Shilpi Dhawan, Lalit Lakhwani   +25 more
doaj   +1 more source

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model

International Journal of Ophthalmology, 2013
AIM:To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model.METHODS:Sixteen corneas of 16 rats were chemically cauterized and ...
Cem Küçükerdönmez, Veysi Öner, Ebru Eren Akar, Yonca Aydın Akova   +3 more
doaj   +1 more source